- Home
- EIC vs ITOS Comparison
EIC vs ITOS Comparison
Compare EIC & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EIC
- ITOS
- Stock Information
- Founded
- EIC N/A
- ITOS 2011
- Country
- EIC United States
- ITOS United States
- Employees
- EIC N/A
- ITOS N/A
- Industry
- EIC Finance/Investors Services
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EIC Finance
- ITOS Health Care
- Exchange
- EIC Nasdaq
- ITOS Nasdaq
- Market Cap
- EIC 341.0M
- ITOS 381.2M
- IPO Year
- EIC 2019
- ITOS 2020
- Fundamental
- Price
- EIC $13.74
- ITOS $10.16
- Analyst Decision
- EIC Strong Buy
- ITOS Hold
- Analyst Count
- EIC 1
- ITOS 6
- Target Price
- EIC $17.50
- ITOS $10.60
- AVG Volume (30 Days)
- EIC 291.4K
- ITOS 914.0K
- Earning Date
- EIC 08-05-2025
- ITOS 08-07-2025
- Dividend Yield
- EIC 17.47%
- ITOS N/A
- EPS Growth
- EIC N/A
- ITOS N/A
- EPS
- EIC 0.55
- ITOS N/A
- Revenue
- EIC $51,224,692.00
- ITOS $35,000,000.00
- Revenue This Year
- EIC $42.67
- ITOS N/A
- Revenue Next Year
- EIC $29.16
- ITOS N/A
- P/E Ratio
- EIC $24.91
- ITOS N/A
- Revenue Growth
- EIC 68.61
- ITOS 177.89
- 52 Week Low
- EIC $12.63
- ITOS $4.80
- 52 Week High
- EIC $16.71
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- EIC 56.13
- ITOS 67.13
- Support Level
- EIC $13.32
- ITOS $9.95
- Resistance Level
- EIC $13.83
- ITOS $10.20
- Average True Range (ATR)
- EIC 0.19
- ITOS 0.16
- MACD
- EIC 0.09
- ITOS -0.10
- Stochastic Oscillator
- EIC 86.36
- ITOS 84.75
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.